You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Jazz Pharmaceuticals reported record revenue of $1.24 billion, up 10%, and raised 2026 revenue guidance to 4.775 to 4.85 billion dollars. Zihara generated $21 million and has peak sales potential of $3 to $5 billion.
Jazz Pharmaceuticals plc reported approximately 17,550 active Xywav patients exiting the third quarter of 2026, FDA approval of two first-line Ziihera GEA regimens in August 2026, and Zepzelca’s second-line indication removal on September 30, 2026.
Jazz Pharmaceuticals reported record 3Q26 revenue of $1.2 billion (+10% YoY), raised 2026 revenue guidance to $4.775 - $4.85 billion, and closed the Actio acquisition in September 2026, adding ABS-1230 (JZP6979) to its rare epilepsy portfolio.
Jazz Pharmaceuticals estimates the Actio Biosciences acquisition, completed September 15, 2026, will produce a pre-tax acquired IPR&D charge of approximately $755 million in the third quarter of 2026, unfavorable by approximately $11.00 to both GAAP EPS and non-GAAP adjusted EPS.
Jazz Pharmaceuticals plc announced Samantha Pearce plans to retire as Chief Commercial Officer upon selection and appointment of her successor or by June 30, 2027, and will search internal and external candidates.
On September 23, 2026, Jazz Pharmaceuticals Public Limited Company repriced $1,895,000,000 of term loans, extending maturity to May 5, 2033 from May 5, 2028 and lowering applicable margins by 50 basis points.
